Compare VENUS REMEDIES with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES GSK PHARMA VENUS REMEDIES/
GSK PHARMA
 
P/E (TTM) x -1.1 51.3 - View Chart
P/BV x 0.1 10.8 0.7% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 VENUS REMEDIES   GSK PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
GSK PHARMA
Mar-19
VENUS REMEDIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1263,595 3.5%   
Low Rs611,253 4.9%   
Sales per share (Unadj.) Rs301.8184.7 163.4%  
Earnings per share (Unadj.) Rs-24.926.3 -94.6%  
Cash flow per share (Unadj.) Rs2.529.2 8.7%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs293.3126.3 232.2%  
Shares outstanding (eoy) m12.34169.40 7.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.313.1 2.4%   
Avg P/E ratio x-3.892.2 -4.1%  
P/CF ratio (eoy) x36.783.1 44.2%  
Price / Book Value ratio x0.319.2 1.7%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m1,154410,626 0.3%   
No. of employees `0000.95.0 18.6%   
Total wages/salary Rs m3935,372 7.3%   
Avg. sales/employee Rs Th4,026.16,306.7 63.8%   
Avg. wages/employee Rs Th425.01,083.1 39.2%   
Avg. net profit/employee Rs Th-331.8898.0 -36.9%   
INCOME DATA
Net Sales Rs m3,72431,281 11.9%  
Other income Rs m231,023 2.2%   
Total revenues Rs m3,74732,304 11.6%   
Gross profit Rs m3956,009 6.6%  
Depreciation Rs m338486 69.6%   
Interest Rs m3546 5,905.0%   
Profit before tax Rs m-2756,540 -4.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m322,373 1.3%   
Profit after tax Rs m-3074,454 -6.9%  
Gross profit margin %10.619.2 55.2%  
Effective tax rate %-11.536.3 -31.6%   
Net profit margin %-8.214.2 -57.9%  
BALANCE SHEET DATA
Current assets Rs m2,63820,061 13.1%   
Current liabilities Rs m2,30514,543 15.8%   
Net working cap to sales %8.917.6 50.7%  
Current ratio x1.11.4 83.0%  
Inventory Days Days13557 238.6%  
Debtors Days Days4614 329.5%  
Net fixed assets Rs m4,87114,343 34.0%   
Share capital Rs m1231,694 7.3%   
"Free" reserves Rs m3,49619,704 17.7%   
Net worth Rs m3,61921,398 16.9%   
Long term debt Rs m1,3742 68,720.0%   
Total assets Rs m7,50939,113 19.2%  
Interest coverage x0.21,091.0 0.0%   
Debt to equity ratio x0.40 406,313.9%  
Sales to assets ratio x0.50.8 62.0%   
Return on assets %0.611.4 5.5%  
Return on equity %-8.520.8 -40.7%  
Return on capital %1.631.9 5.0%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m0534 0.0%   
Fx outflow Rs m5177,091 7.3%   
Net fx Rs m-517-6,557 7.9%   
CASH FLOW
From Operations Rs m5143,994 12.9%  
From Investments Rs m-123-1,433 8.6%  
From Financial Activity Rs m-387-3,584 10.8%  
Net Cashflow Rs m4-1,023 -0.4%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.2 10.2 1.8%  
FIIs % 0.6 23.8 2.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 15.4 431.2%  
Shareholders   20,121 102,036 19.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   UNICHEM LAB  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 13, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS